Thoratec Corporation

Skip to content

Overview

Webcast ImageWebcast
Q2 2015 Thoratec Corporation Earnings Conference Call (Replay)
08/04/15 at 1:30 p.m. PT
THOR (Common Stock)
Price63.35Change- 0.09
Volume766,419% Change0.14%
08/04/2015 4:00 p.m. ETPricing delayed 20 minutes

Thoratec is the world leader in mechanical circulatory support with the broadest product portfolio to treat the full range of clinical needs for patients suffering from advanced heart failure. The company's products include the HeartMate LVAS and Thoratec VAD, with more than 20,000 devices implanted in patients suffering from heart failure. Thoratec also manufactures and distributes the CentriMag and PediMag / PediVAS product lines. Thoratec is headquartered in Pleasanton, California. For more information, visit www.thoratec.com.

Recent News

More >>
DateTitle 
08/04/15Thoratec® Reports Second Quarter 2015 Results
- Revenue of $128.7 million for the second quarter of 2015 - Worldwide HeartMate pump unit growth of 20% - GAAP net income per diluted share of $0.24, and non-GAAP net income per diluted share of $0.37 - No financial guidance due to pending transaction PLEASANTON, Calif., Aug. 4, 2015 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in mechanical circulatory support (MCS) therapies to save, support and restore failing hearts, today reported its financial results fo... 
Printer Friendly Version
07/22/15St. Jude Medical and Thoratec Announce Definitive Agreement
Combination Accelerates Innovation-Based Growth Program and Expands Heart Failure Franchise St. Jude Medical Will Discuss Transaction on its Second Quarter 2015 Earnings Call Scheduled for 8 a.m. EDT (7 a.m. CDT) on July 22, 2015 ST. PAUL, Minn. & PLEASANTON, Calif.--(BUSINESS WIRE)--Jul. 22, 2015-- St. Jude Medical (NYSE:STJ) and Thoratec (NASDAQ:THOR) today announced that the Boards of Directors of both companies have unanimously approv... 
Printer Friendly Version
07/22/15Thoratec Announces Preliminary Second Quarter Revenue
PLEASANTON, Calif., July 22, 2015 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in mechanical circulatory support therapies to save, support and restore failing hearts, announced preliminary unaudited revenue in the range of $128 million to $129 million for the second quarter of 2015. "Our strong second quarter performance resulted from a broad increase in utilization of our products globally, driven in particular by favorable trends in our North American HeartMate franc... 
Printer Friendly Version

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.